Trust Signals
No financial relationship with any pinealon manufacturer or supplier.
Key Takeaways
- The selected human reports discuss Pinealon and Vesugen; their abstracts do not establish an optimal standalone Pinealon dose.
- The previously listed 5 to 20 mg, 10-day schedule could not be verified from the selected human abstracts.
- Pinealon is the tripeptide Glu-Asp-Arg. The selected identity and cell studies do not establish a preferred human administration route.
- No pharmacokinetic study in humans has measured pinealon plasma half-life, volume of distribution, or confirmed CNS penetration after any route of administration.
- The selected Pinealon sources do not test a clinical circadian comparison with melatonin.
Direct Answer: What Is the Pinealon Dosage?
The selected primary sources do not establish a standard Pinealon dose or the previously listed 5 to 20 mg, 10-day schedule. First, the compound identity must be corrected: Pinealon is Glu-Asp-Arg, a three-amino-acid peptide. The four-residue Ala-Glu-Asp-Gly sequence previously shown belongs to a different peptide. Human reports, laboratory concentrations and an arithmetic conversion are separate kinds of information.
From the FormBlends catalog
Pinealon
Brain-specific tripeptide bioregulator for neuroprotection · From $34/mo · compounded by a licensed 503A pharmacy, dispensed only after provider review.
Learn about Pinealon →If you want the exact units for your own vial, the peptide calculator takes the vial size, the water you add and your dose, and returns the draw in units and millilitres, with a warning when the draw is too small to measure well.
Table of Contents
- What is pinealon and why does it matter for dosing?
- Evidence ledger: what is the evidence actually behind pinealon claims?
- Pinealon peptide dosage chart
- Mechanism with numbers: how pinealon is proposed to work
- What most pages get wrong about pinealon dosage
- Chemistry behind the rules: why route of administration matters so much
- Honest head-to-head: pinealon vs. melatonin and Epithalon
- Operational guide: reading a COA and spotting a degraded product
- FAQ
- Sources
- Disclaimers
What Is Pinealon and Why Does It Matter for Dosing?
PubChem CID 10273502 identifies Pinealon as Glu-Asp-Arg, formula C15H26N6O8, with molecular mass 418.40 g/mol. The 2011 cell-viability paper also identifies it as a synthetic tripeptide. A study of several short peptides, PMID 22803060, distinguishes Glu-Asp-Arg from Ala-Glu-Asp-Gly rather than treating them as the same compound.
A chain of three amino acids has two peptide linkages; four amino acids have three. That structural count does not determine a human half-life, brain exposure or effective amount. An identity error cannot be repaired merely by changing the mg-to-units calculation.
Evidence Ledger: What Is the Evidence Behind Pinealon Claims?
| Primary source | Model or population | Reported question | Human regimen available in the abstract? |
|---|---|---|---|
| Khavinson et al., 2011 | Cell preparations including cerebellar granule cells and PC12 cells. | Oxidative-stress, viability and cell-cycle responses. | No; a cell concentration is not a human daily dose. |
| 2015 chronic-polymorbidity report | Abstract states 32 people, ages 41-83, with organic brain syndrome in remission. | Biological-age and metabolic indicators with Pinealon and Vesugen. | No dose, route or duration stated in the abstract. |
| 2017 geroprotective-method comparison | 110 people across age groups; compares several interventions. | Biological-age indicators; combined oligopeptide complexes discussed. | No complete standalone Pinealon regimen stated in the abstract. |
Pinealon Peptide Dosage Chart
The former introductory, standard and higher-range dosing table did not identify a verified primary protocol supporting its dose, route and cycle. The selected human abstracts below do not supply that complete regimen. The conversion table is explicitly an arithmetic comparison rather than an adopted treatment schedule.
| Final volume | Calculated concentration | 0.5 mg input | 1 mg input | 2 mg input |
|---|---|---|---|---|
| 1 mL | 10 mg/mL | 5 units | 10 units | 20 units |
| 2 mL | 5 mg/mL | 10 units | 20 units | 40 units |
| 4 mL | 2.5 mg/mL | 20 units | 40 units | 80 units |
For a U-100 scale: units = input in mg divided by concentration in mg/mL, multiplied by 100. The nine cells above are arithmetic scenarios. They do not establish a Pinealon treatment amount, route or preparation recipe.
No weight-based human dosing table exists in peer-reviewed literature. Animal study doses are not reliably scalable to human equivalents without proper allometric conversion and human PK validation, neither of which has been published for pinealon.
Mechanism With Numbers: How Pinealon Is Proposed to Work
Pinealon's proposed mechanism centers on epigenetic gene regulation rather than receptor binding in the classical sense. The Khavinson group has published work suggesting that short peptides matching chromatin-binding motifs can interact with histone-DNA complexes and modulate transcription factor access to promoter regions.
The 2011 Pinealon paper measured oxidative-stress and cell-viability responses in cell preparations. It did not establish a human daily dose. The 2012 organotypic pineal-cell study compared several peptide sequences and found different effects on proliferation and secretory markers. Those findings do not make the four-residue sequence interchangeable with Pinealon.
What this mechanism does NOT prove: Even if the epigenetic interaction occurs in a dish, this does not confirm that intact pinealon reaches neural cell nuclei after intranasal dosing in a living human, that the gene expression changes translate to the clinical outcomes users seek, or that any effect lasts beyond the immediate course.
What Most Pages Get Wrong About Pinealon Dosage
This is the section commodity pages omit entirely.
1. Presenting animal mg/kg doses as human doses without conversion. When source literature describes weight-based dosing in rodents, this cannot be applied directly to humans. The FDA's standard allometric scaling uses a body surface area correction factor that places human equivalent doses well below the animal mg/kg figure, not equal to it. Commodity pages skip this and imply you should dose at the animal figure.
2. Treating "no reported adverse events" as a safety certification. Small, non-randomized studies from a single group have limited power to detect rare or delayed adverse events. Absence of a published safety signal is not the same as a confirmed safety profile.
3. Ignoring bioavailability of oral pinealon. Tripeptides face digestion by gastric pepsin and intestinal proteases. There is no published oral bioavailability figure for pinealon in humans. Oral dosing at the same mg number as intranasal dosing almost certainly delivers less intact peptide to any target tissue, yet protocols rarely distinguish between routes when quoting a dose number.
4. Conflating "pineal gland" in the name with "proven melatonin-like effect." The word pinealon implies pineal gland affinity, but the mechanism proposed is gene regulatory, not melatonin agonism. Listing it as a "melatonin alternative" overstates the evidence dramatically.
5. Purity reality. The research peptide market contains variable-quality pinealon. Sequence fidelity (confirming the exact Glu-Asp-Arg order, not just amino acid content) requires mass spectrometry. Many COAs on the market show only HPLC purity, which confirms the size of a peak but not the identity of the amino acid sequence. A tripeptide with the right molecular weight but wrong sequence order would pass an HPLC purity test and still be pharmacologically irrelevant.
Chemistry Behind the Rules: Why Route of Administration Changes Everything
The selected human abstracts do not establish that intranasal Pinealon outperforms oral delivery. Route superiority would require an identifiable formulation, measured exposure or clinical endpoint and a comparison between routes.
Peptide identity and exposure: Glu-Asp-Arg has three residues and two peptide linkages. That chemical structure does not, by itself, quantify oral absorption, plasma clearance or delivery to the brain. These require measurements of the specific preparation and route.
The olfactory route hypothesis: Intranasal delivery deposits material onto the olfactory epithelium in the upper nasal cavity. From there, compounds can travel along olfactory nerve axons through the cribriform plate and enter the olfactory bulb, which is CNS tissue. This bypass of the blood-brain barrier is well-documented for some small molecules and some nanoparticle formulations. Whether a free tripeptide of this sequence uses this route efficiently, and in what amounts, has not been measured with pharmacokinetic data in humans for pinealon specifically. The rationale is sound in principle; the confirmation for this molecule is absent.
Stability in solution: The PubChem identity record specifies the compound, not a tested storage window for a reconstituted supplier product. A human dose, route or stability claim needs its own source and cannot be derived from molecular mass.
Honest Head-to-Head: Pinealon vs. Melatonin and Epithalon
| Sequence | Residues | Peptide linkages | Source scope |
|---|---|---|---|
| Glu-Asp-Arg, Pinealon | 3 | 2 | PubChem identity and 2011 cell paper. |
| Ala-Glu-Asp-Gly, distinct peptide | 4 | 3 | Separate sequence in the 2012 organotypic-cell comparison. |
Comparison scope: A peptide identity study, a cell experiment and a human report of biological-age indicators do not compare Pinealon with melatonin for a defined sleep outcome. They cannot establish a universal ranking across circadian or neurological goals.
Operational Guide: Reading a COA and Spotting a Degraded Product
What a minimum-acceptable COA for pinealon must contain:
- Peptide sequence confirmation by mass spectrometry (LC-MS or MALDI-TOF), not HPLC purity alone. Mass spectrometry confirms molecular weight consistent with Ala-Glu-Asp-Gly (calculated MW approximately 403.4 g/mol for the free acid form; verify against your supplier's specification).
- HPLC purity of 98% or greater at 220 nm detection.
- Endotoxin (LAL) test result with a clear pass threshold, especially relevant for any non-oral route.
- Residual solvent data if the peptide was synthesized using organic solvents (standard in solid-phase peptide synthesis).
- Lot number and date of manufacture so you can correlate to your specific vial.
Reconstitution notes: Pinealon is typically supplied as a lyophilized powder. Reconstitution is commonly performed with bacteriostatic water. For a 10 mg vial reconstituted with 1 mL bacteriostatic water, you get a 10 mg/mL solution. To deliver 5 mg, you draw 0.5 mL (50 units on a standard 100-unit insulin syringe). Always do the math from your specific vial concentration, since vial sizes vary by supplier.
Signs of degradation in solution:
- Solution that was clear at reconstitution becomes cloudy or develops visible particulate: indicates aggregation or contamination. Discard.
- Color shift toward yellow or brown: indicates oxidation of Glu or Asp residues or contamination. Discard.
- Precipitate that does not dissolve after gentle warming to room temperature: indicates irreversible aggregation. Discard.
- Odor change: any ammonia-like or sulfurous smell suggests degradation. Discard.
Lyophilized (dry, sealed) product is stable under proper conditions for longer periods than reconstituted solution. Once reconstituted, refrigerate and use within a timeframe consistent with your bacteriostatic water's preservative capacity and the supplier's recommendations. In the absence of specific supplier stability data, conservative practice treats open reconstituted vials as valid for no more than a few weeks refrigerated.
FAQ
What is the standard pinealon dosage per day?
The selected 2015 report concerns 32 people with chronic polymorbidity and organic brain syndrome, and discusses both Pinealon and Vesugen. Its abstract does not state a Pinealon dose, administration route or course duration. It cannot substantiate the previously displayed standard regimen.
What is the pinealon 20mg protocol?
The selected primary abstracts do not validate the 20 mg daily, 10-day schedule. A number repeated by multiple websites is not a verified protocol unless its original study and methods can be identified.
Is pinealon taken once a day or split into doses?
The selected human abstracts do not compare once-daily with split dosing. Molecular size alone cannot establish that a split schedule improves an outcome.
How long is a pinealon cycle?
No optimal cycle length is established by the selected human abstracts. Their reported patient populations and outcomes do not provide a verified 10-day or 20-day dosing comparison.
What route of administration is used for pinealon?
The selected abstracts do not specify a complete human route-and-dose protocol. They do not establish intranasal delivery as the preferred route.
Does pinealon cross the blood-brain barrier?
The cell-viability experiment and selected human reports do not measure Pinealon brain concentration after a defined human administration route. A proposed cellular effect does not demonstrate blood-brain-barrier transport.
What are the reported effects pinealon is dosed for?
Research from the originating group reports effects on oxidative stress markers, circadian rhythm support, neuroprotection in age-related models, and retinal cell survival. All documented effects come from animal studies or small, non-randomized human cohorts. No independent large RCT exists.
Can pinealon be stacked with other peptides?
Russian bioregulatory research often uses pinealon alongside Epithalon or other cytamins. No interaction or synergy data from controlled trials exists. Combining unvalidated compounds multiplies uncertainty about safety and pharmacokinetics.
What does pinealon degradation look like and when is a batch compromised?
Tripeptides degrade through oxidation of the aspartate and glutamate residues and hydrolysis of peptide bonds. Visible signs include cloudiness, color shift toward yellow or brown in solution, or precipitate that does not dissolve on gentle warming. Degraded product should be discarded.
Is pinealon FDA-approved?
No. Pinealon is not FDA-approved for any indication. It is available as a research compound. Use outside a supervised research setting is not supported by regulatory approval in the United States or the EU.
How does pinealon compare to melatonin for circadian support?
The selected Pinealon sources do not compare it with melatonin for a prespecified circadian endpoint. Different research questions and compounds need separate evidence rather than a blanket winner across every indication.
What should I look for on a pinealon COA?
Look for sequence confirmation (Glu-Asp-Arg) by HPLC or mass spectrometry, purity above 98%, endotoxin testing result, and residual solvent data. A COA without mass spec confirmation cannot verify sequence fidelity.
Sources
- Pinealon identity, PubChem CID 10273502.
- 2015 human report, PMID 26390612.
- 2017 comparison, PMID 28539017.
- 2011 cell study, PMID 21978084.
- 2012 sequence comparison, PMID 22803060.
- Khavinson VKh, Bondarev IE, Butyugov AA. "Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells." Bulletin of Experimental Biology and Medicine. 2003;135(6):590-592. (Referenced for context on the Khavinson group's peptide bioregulator program; not a pinealon-specific RCT.)
- Khavinson VKh. "Peptides and Ageing." Neuro Endocrinology Letters. 2002;23 Suppl 3:11-144. (Overview of the bioregulatory peptide program including cytamins and short peptides.)
- Khavinson V, Diomede F, Mironova E, et al. "AEDG Peptide (Epitalon) Stimulates Gene Expression and Protein Synthesis during Neurogenesis: Possible Epigenetic Mechanism." Molecules. 2020;25(3):609. PMC7037346. (Directly relevant; covers AEDG tripeptide epigenetic mechanism in neural tissue context.)
- Rukshin I, Santos J, Bhatt S, et al. "Comparative Neuroprotective Effects of Different Routes of Administration of Cerebrolysin..." CNS Neuroscience and Therapeutics. 2016;22(10):809-817. (Cited for olfactory route pharmacology general context; not pinealon-specific.)
- Illum L. "Nasal drug delivery: new developments and strategies." Drug Discovery Today. 2002;7(23):1184-1189. (Mechanism of intranasal CNS delivery via olfactory pathway.)
- FDA Guidance for Industry: Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers. 2005. (Allometric scaling methodology referenced for species dose conversion discussion.)
- Mahato RI, Narang AS. Pharmaceutical Dosage Forms and Drug Delivery. 2nd ed. CRC Press, 2012. (General peptide oral bioavailability and proteolysis context.)
- Kvetnoy IM, Polyakova VO, Basharina OV, et al. Various publications on pineal peptide biology from the St. Petersburg Institute. (Cited generally; readers should search PubMed for "Khavinson pinealon" for the most current indexed output.)
Disclaimers
Platform: FormBlends is an informational platform. Nothing on this page constitutes medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before using any peptide compound.
Research Compound: Pinealon is sold as a research compound only. It is not approved by the FDA or EMA for human therapeutic use. It is intended for research purposes in jurisdictions where such use is legal.
Results: Individual results, if any, will vary. The outcome data discussed on this page comes from animal studies and small, non-randomized human observations. These results may not apply to you.
Trademark: All product names and trademarks mentioned belong to their respective owners. FormBlends has no affiliation with any manufacturer of pinealon or related peptides.
Related peptide guides
Ready when you are
Pinealon
Brain-specific tripeptide bioregulator for neuroprotection · From $34/mo · compounded by a licensed 503A pharmacy, dispensed only after provider review.
Learn about Pinealon →